Loading organizations...
3H Health Investment is a private equity and venture capital firm based in Hong Kong with an additional branch in Shanghai, focusing on early-stage, growth, and expansion opportunities within the healthcare and life sciences sectors. The firm provides capital and strategic support to companies developing medical innovations, biopharmaceuticals, and healthcare technologies. Operating through a team of four primary investment decision-makers, the organization currently manages three distinct private equity funds. The firm's investment portfolio and historical transaction involvement feature prominent pharmaceutical and medical technology companies, including CSPC, Simcere, and Consun. Additionally, the firm's leadership has been involved in significant industry transactions, such as the acquisition of Dihon by Bayer AG. 3H Health Investment was founded in July 2016 by Managing Partner Mr. Wang alongside other founding partners.
Key people at 3H Health Investment.
The firm concentrates on biotechnology and pharmaceuticals, as well as medical technology, with a focus on underlying technology platforms and key sectors.
3H Health Investment maintains operational bases in both Hong Kong and Shanghai.
The firm concentrates on biotechnology and pharmaceuticals, as well as medical technology, with a focus on underlying technology platforms and key sectors.
3H Health Investment maintains operational bases in both Hong Kong and Shanghai.
Key people at 3H Health Investment.
3H Health Investment has 6 tracked investments across 4 companies. The latest tracked deal is $130.0M Series D in Angitia Biopharmaceuticals in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 5, 2026 | Angitia Biopharmaceuticals | $130.0M Series D | Frazier Life Sciences, Venrock | Ascenta Capital, Bain Capital Life Sciences, BlackRock, BVF Partners, Elikon Venture, Hillhouse Capital Group, Janus Henderson Investors, Legend Capital, Logos Capital, Morningside, OrbiMed, RA Capital Management, TF Capital, Yonghua Capital |
| Dec 11, 2024 | Angitia Biopharmaceuticals | $120.0M Series C | Bain Capital Life Sciences | Janus Henderson Investors, Legend Capital, OrbiMed, Yonghua Capital |
| Oct 25, 2023 | Angitia Biopharmaceuticals | $46.0M Series B Extension | Morningside Ventures | Legend Capital, OrbiMed |
| Apr 19, 2023 | Chamlion | $34.3M Series B | 3H Health Investment | Taihe Capital |
| Apr 21, 2021 | EdiGene | $61.5M Series B | Andy LIN | Hongshan Capital Group (Sequoia Capital China), Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Ventures, Sherpa Healthcare Partners |
| Dec 10, 2019 | Imperative Care | $85.0M Series C | Frank YU, Andrew Hack | Ascension Ventures, Delos Capital, Incept, Rock Springs Capital |
